What were the key takeaways from Clearwater Analytics's earnings call?

What guidance did Clearwater Analytics's management provide for the next earnings period?

What were the key takeaways from Clearwater Analytics’s earnings call?

What factors drove the changes in Clearwater Analytics's revenue and profit?

Did Clearwater Analytics beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for Clearwater Analytics year over year?

What is Clearwater Analytics's latest dividend and current dividend yield?

What is the market's earnings forecast for Clearwater Analytics next quarter?

- **Revenue Growth**: Q3 2025 revenue up 77% YoY to $205.1M, driven by acquisitions and cross-selling.
- **Margin Expansion**: EBITDA margin 34.5%, GenAI reducing manual processes by 90%.
- **Strategic Focus**: $23B TAM in alternatives, risk, and global markets.
- **2026 Outlook**: 12%+ Enfusion growth, 70% cross-sell booking growth.

**【CEO Summary Section】**
- Q3 2025 revenue reached $205.1 million, up 77% year-over-year, driven by the integration of Enfusion, Beacon, and Bistro acquisitions.
- Gross margin improved to 78.5%, exceeding 2027 targets, with GenAI adoption reducing manual processes by 90%.
- Cross-selling of risk and alternative asset solutions (e.g., LPx, MLx) grew 70% year-over-year, with asset management becoming the largest booking segment.
- TAM expanded to $23 billion, with focus on alternatives, risk, and global markets.

**【CFO Financial Commentary】**
- EBITDA of $70.7 million (34.5% margin) exceeded guidance, enabling debt reduction and share buybacks.
- Organic ARR growth of $22 million (Q3) reflects core Clearwater resilience.
- 2025 full-year revenue guidance: $730-731 million (+62% YoY), with EBITDA of $247 million.
- Commercial model alignment for Enfusion clients to accelerate 2026 growth.

**【Q&A Highlights】**
- Cross-selling of risk and alternative solutions (e.g., Beacon, Bistro) driving 70% booking growth.
- GenAI adoption reduces reconciliation time by 90%, supporting 82% gross margin for core clients.
- 2026 focus on asset management and risk solutions for 12%+ Enfusion growth.
- 98% gross retention and 108% net retention reflect client loyalty and product expansion.

Clearwater Analytics Holdings, Inc. (CWAN) Q3 2025 Earnings Call Transcript

- **Record Growth**: Q2 revenue of $181.9 million (+70% YoY) and ARR of $783.5 million (+83.4% YoY) reflect strong organic and acquisition-driven expansion.
- **Margin Triumph**: 77.4% gross margin exceeded expectations, with core business exceeding 80%, despite integrating lower-margin Enfusion.
- **Strategic Wins**: Signed VKB, Germany's largest insurer, and partnered with Bloomberg for asset managers, showcasing front-to-back platform capabilities.
- **Synergy Achievement**: Delivered $20 million in synergies within the first quarter, with focus shifting to growth.
- **Future Momentum**: Q3 guidance of $203-$204 million revenue and $65 million EBITDA signals confidence in 20%+ core growth and margin expansion.

**【CEO Summary Section】**
- **Revenue Growth**: Total revenue reached $181.9 million, up 70% YoY, with core Clearwater revenue growing 22% organically.
- **ARR Expansion**: Annualized recurring revenue (ARR) rose to $783.5 million, a 83.4% YoY increase, driven by organic growth and acquisitions.
- **Profitability**: Adjusted EBITDA of $58.3 million (32.1% of revenue) reflected a 74.3% YoY improvement, exceeding expectations despite integrating lower-margin businesses.
- **Gross Margin Achievement**: Delivered 77.4% gross margin, surpassing the 76.5% blended target, with core business exceeding 80%.
- **Strategic Integration**: Acquired Enfusion, Beacon, and Bistro, achieving $20 million in synergies within the first quarter. Cross-selling opportunities and a front-to-back platform vision are key growth drivers.
- **Client Engagement**: Engaged over 450 clients globally, with near-unanimous enthusiasm for the integrated platform. New wins include VKB, Germany's largest public insurer, and partnerships with Bloomberg for asset managers.
- **Future Phases**: Transitioning to Phase 2, focusing on cross-selling and product launches, with Phase 3 targeting a fully integrated platform.

**【CFO Financial Commentary】**
- **Revenue Beat**: Exceeded Q2 guidance by $7.9 million, with core business and acquisitions outperforming expectations.
- **EBITDA Guidance**: Q3 EBITDA expected at $65 million (32% margin), with full-year guidance of $232-$237 million.
- **Debt Management**: Repaid $50 million of revolver debt, targeting leverage below 4x by year-end.
- **Expense Control**: Achieved $20 million in expense synergies, enabling focus on growth.
- **Long-Term Outlook**: Confident in 20%+ core growth and margin expansion through operational efficiency and AI adoption.

**【Q&A Highlights】**
- **Organic Growth Acceleration**: Q2 organic ARR of $513 million (20% YoY) expected to accelerate in Q3/Q4, with sequential revenue growth reaccelerating.
- **Enfusion Performance**: Delivered highest bookings in history, with 49 new clients, targeting 20% growth over 2 years.
- **Cross-Sell Potential**: Risk capabilities and front-to-back solutions (e.g., VKB deal) drive immediate cross-sell opportunities, with generative AI set to enhance offerings.
- **NRR Trends**: Core NRR at 114%, consolidated NRR at 110%, with plans to improve Enfusion NRR to 115% over time.
- **Tokenization Impact**: Positioning as a leader in alternative asset management with single security master, enabling real-time risk and cash flow insights.
- **Generative AI Investment**: Early efficiency gains expected to transition to revenue growth in 2026, with competitive advantage in data integration.


Clearwater Analytics Holdings, Inc. (CWAN) Q2 2025 Earnings Call Transcript

- **Record Q1 Growth**: 23.5% YoY revenue ($126.9M), 22.7% ARR growth ($493.9M), and 40% EBITDA expansion ($45.1M). Gross margin at 78.9%, near 80% target.
- **Acquisition Strategy**: Integrating Enfusion, Beacon, and Bistro into a unified front-to-back platform, with Phase 1 focusing on standalone growth and Phase 3 on full integration by 2027.
- **Profitability Leap**: Gross margin improved 370bps since FY2022, exceeding 50bps/year target. EBITDA margin at 35.5%, up 420bps YoY.
- **Enfusion Outlook**: 13% Q1 growth to accelerate to 20% by 2027, driven by Clearwater cross-selling and R&D synergies.
- **2025 Guidance**: $720-728M revenue (59-61% growth) and $230-235M EBITDA (32% margin), with 19% revenue in equity comp.


**【CEO Summary Section】**
- Q1 2025 revenue reached $126.9 million, up 23.5% YoY, with ARR of $493.9 million (22.7% YoY growth). Adjusted EBITDA was $45.1 million (35.5% of revenue), up 40% YoY. Gross margin improved to 78.9%, nearing the long-term target of 80%.
- Strategic acquisitions of Enfusion, Beacon, and Bistro aim to create the industry's first fully integrated front-to-back office platform. Phase 1 focuses on standalone growth, Phase 2 on cross-selling, and Phase 3 on full platform integration.
- NRR reached 115% in 2024, ahead of the 2026 target. Key wins include a tech leader adopting PRISM and a German insurance company replacing a competitor's solution.
- Gross margin improved 370bps over FY2022, exceeding the 50bps/year target. Helios reconciliation tool reduced client onboarding time to 5.5 months.

**【CFO Financial Commentary】**
- Q1 GAAP net income was $6.9 million, with free cash flow of $23 million (168% YoY growth). R&D spend was $37.4 million (21.6% of revenue), reflecting scale leverage.
- Full-year 2025 guidance: $720-728 million revenue (59-61% YoY growth) and $230-235 million EBITDA (32% margin). Enfusion contributed $54.5 million in Q1 2025, growing 13% YoY.
- Equity-based compensation is expected to be 19% of revenue in 2025, down from 21.7% in Q1. Depreciation/amortization is $100-120 million.

**【Q&A Key Highlights】**
- **Enfusion Growth**: Expected to accelerate from 13% in Q1 to 20% by 2027, with Phase 1 focusing on Clearwater cross-selling and Phase 2 on R&D integration.
- **Bistro Integration**: Will be a horizontal capability for alternative asset visualization, with Blackstone's use case as a reference.
- **Macro Impact**: Q1 churn and booking stable despite market volatility; revenue protected by commercial model.
- **Synergies**: $20 million in cost savings and 400bps gross margin improvement in Year 1, with full platform integration targeting 2027.
- **Organic Growth**: Clearwater and Beacon expected to maintain 20%+ organic growth, with Enfusion reaccelerating in 2026.


Clearwater Analytics (CWAN)-30 Apr 25-2025 Q1 Earnings call transcript

- **Record Growth**: Q4 2024 revenue up 28% YoY to $126.5M, ARR hits $474.9M (25% YoY), NRR 116%. 
- **Margin Power**: Gross margin 78.8% (190bps YoY expansion), targeting >80% long-term. 
- **Enfusion Synergy**: $5.9B TAM expansion via front-to-back platform, 2025 cross-sell/upsell pipeline. 
- **AI Efficiency**: 50bps annual margin target, AI reducing reconciliation costs by 50%. 
- **Regulatory Tailwind**: NAIC rule changes drove $3M Q4 revenue, ongoing compliance demand. 
- **2025 Outlook**: 19-20% revenue growth, 34% EBITDA margin, $535M+ ARR. 


**【CEO Opening Remarks】**
- Q4 2024 revenue: $126.5M (28% YoY growth), ARR: $474.9M (25% YoY growth), NRR: 116%, Adjusted EBITDA: $41.7M (33% of revenue). 
- Gross margin expanded 190bps YoY to 78.8%, targeting +50bps in 2025 and >80% long-term. 
- Enfusion acquisition to create front-to-back investment platform, with synergies in client expansion, margin improvement, and international growth. 
- Key wins include insurance firms, asset managers, and public sector clients, driven by platform scalability and AI-driven efficiency. 

**【CFO Financial Highlights】**
- Full year 2024 revenue: $451.8M (22.7% YoY), EBITDA: $145.7M (37.6% YoY growth). 
- Q4 2024 gross margin: 78.8%, EBITDA margin: 33% (vs. 20.6% in Q4 2023). 
- 2025 guidance: Revenue $535.5M-$542M (19-20% YoY), EBITDA $182M-$185M (34% margin). 
- Free cash flow negative in Q4 due to one-time tax payment, but AR days improved to 77 days. 

**【Q&A Key Themes】**
- **Enfusion Integration**: Targeting 115+ NRR through cross-selling, leveraging single-instance platform, and accelerating 1-to-4bps strategy. 
- **Margin Expansion**: AI-driven efficiency to sustain +50bps annual margin growth, targeting >80% gross margin. 
- **Regulatory Tailwinds**: NAIC rule changes drove $3M incremental Q4 revenue, with ongoing compliance needs for insurers. 
- **Client Expansion**: 100 clients with >$1M ARR, +14% YoY, driven by upsell (7%), cross-sell (3%), and AUM growth. 
- **FX Impact**: 18% of revenue international, but natural hedge limits EBITDA impact; India workforce provides cost tailwind. 


Actual	0.0368	0.06	0.05	0.05	0.06	0.07	0.07	0.08	0.09	0.1	0.1	0.1	0.12	0.13	0.13	0.12	0.14	0.15
Forecast	0.0223	0.0543	0.0488	0.0516	0.0489	0.063	0.0592	0.0682	0.077	0.0795	0.0897	0.0985	0.1104	0.1136	0.1238	0.1108	0.1348	0.1486
Surprise	+65.02%	+10.50%	+2.46%	-3.10%	+22.70%	+11.11%	+18.24%	+17.30%	+16.88%	+25.79%	+11.48%	+1.52%	+8.70%	+14.44%	+5.01%	+8.30%	+3.86%	+0.94%

CWAN

CWAN fundamentals

CWAN Q4 2025 Earnings

Earnings Call

You can ask Aime

CWAN

CWAN fundamentals

CWAN Q4 2025 Earnings

Earnings Call

CWAN Earnings Call Summary for Q4/2025 Apr 1, 2026

CWAN Earnings Call Summary for Q3/20255:00 PM on Nov 5, 2025

CWAN Earnings Call Summary for Q2/20255:00 PM on Aug 6, 2025

CWAN Earnings Call Summary for Q1/20255:00 PM on Apr 30, 2025

CWAN Earnings Call Summary for Q4/20245:00 PM on Feb 19, 2025

You can ask Aime